Jesse Keller is a Dermatology physician affiliated with Oregon Health & Science University. OpenAlex indexes 61 publications with 784 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3303 SW Bond Ave
Ch16d
Portland, OR 972394501
Telephone
253-468-2704Registry record last updated 5 Jun 2015.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20258 payments$13,835openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
34.7%Azole Antifungal8.8%Ketoconazole100%Part D≥11 patientsTetracycline-class Drug7.1%Doxycycline Monohydrate100%Part D≥11 patients+ 4 more classes in this area
Nervous system
28.8%Typical Antipsychotic14.1%Pimozide100%Part D≥14 patientsGabapentinoids6.8%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Sensory organs
13.6%Corticosteroid13.6%Clobetasol Propionate58%Hydrocortisone42%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes and mortality in calciphylaxis: A multicenter update
Journal of the American Academy of Dermatology
2025 - Successful Treatment of Delusional Infestation with Dupilumab: Case Report
SKIN The Journal of Cutaneous Medicine
2025 - LB1089 Successful treatment of delusional infestation with dupilumab
Journal of Investigative Dermatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”